Movano Health Applies Advanced AI through Deep Learning to Deliver Improved Accuracy of Heart Rate in Motion

Enhancements address significant clinical enterprise need in wearables for a variety of healthcare applications

Movano Health announced major advances in the accuracy of its heart rate in motion algorithm following the implementation of deep learning into the processing.

Movato Health recently released an engineering accuracy study directed by Movano Health Founder and CTO Michael Leabman, Enhanced Heart Rate in Motion Accuracy with the Evie Ring Using Advanced Deep Learning Algorithms, which demonstrates the value of deep learning integration into heart rate (HR) algorithms for improved accuracy.

“Utilizing deep learning is significantly better than standard techniques as it is the optimal solution for removing the effects of motion, eliminating the noise and motion artifacts in the optical signal,” said Leabman. “We believe that this is a first of its kind implementation and an innovation that has the potential to enhance the reliability of wearable health monitors, providing users with more accurate and consistent heart rate measurements.”

Movato Health Notes…

The study was conducted with 65 subjects, completing 7-10 sessions of various activities including sleeping, resting, walking, running, climbing stairs, working out at the gym, and swimming. Data was collected with the Evie Ring and a Polar H7 chest strap used as a control device. The results demonstrated a high correlation with the Polar H7 chest strap outputs across a diverse data set, confirming the reliable reporting of heart rate by Evie’s HR algorithm across all activities.

To overcome the challenges of measuring heart rate from PPG signals in wearables, Evie’s HR solution combines the best from the signal processing world as well as recent advances in AI-based Deep Learning.

  • Optimally filtering out motion artifacts and more accurately tracking heart rate through development of AI algorithms in a specific, novel Deep Learning solution.
  • Removing motion artifacts from the PPG signal by leveraging both PPG and 3D accelerometer data.
  • Enhancing the signal-to-noise ratio (SNR) through Deep Learning.

The Company plans to convert all Evie Ring algorithms including sleep, respiration, heart rate variability (HRV), and blood oxygen saturation (SpO2) through this same process.

Hot this week

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution

Axlab, Danish Medtech Pioneer, expands to US with Advanced Robotic Tissue Sectioning for Pathology Laboratories

Kris Rokke, National Sales Director for Axlab in the US. "My team and I are extremely excited and honored about this unique opportunity to also offer this advanced technology to labs across the US and thus contribute to the pathology labs of tomorrow."

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.